中国神经再生研究(英文版) ›› 2022, Vol. 17 ›› Issue (2): 344-353.doi: 10.4103/1673-5374.317981

• 原著:退行性病与再生 • 上一篇    下一篇

炎症性肠病与帕金森病的关联:系统评价和荟萃分析

  

  • 出版日期:2022-02-15 发布日期:2021-10-08

Association between inflammatory bowel diseases and Parkinson’s disease: systematic review and meta-analysis#br#

Yu Zhu#, Min Yuan#, Yue Liu, Fang Yang, Wen-Zhi Chen, Zhen-Zhen Xu, Zheng-Bing Xiang*, Ren-Shi Xu*#br#   

  1. Department of Neurology, Jiangxi Provincial People’s Hospital, Affiliated People’s Hospital of Nanchang University, Nanchang, Jiangxi Province, China
  • Online:2022-02-15 Published:2021-10-08
  • Contact: Ren-Shi Xu, MD, PhD, 13767015770@163.com; Zheng-Bing Xiang, MD, xzbshawn@163.com.

摘要:

近年来逐渐有证据指出炎症性肠病(IBD)和帕金森病(PD)之间存在相似的发病机制和密切相关的发病风险,然而流行病学的结果却说法不一。为此,文章系统评价了炎症性肠病与帕金森病发病风险之间的关系。(1)作者检索了PubMed,EMbase和Cochrane数据库建库到2019-10关于帕金森病或炎症性肠病的观察性研究,最终纳入9项观察性研究,包括12,177,520例患者,各文献的NOS评分均未提示高偏倚风险。(2)经过调整混杂因素和剔除异质性文献后分析发现,炎症性肠病和帕金森病的总体关联风险显著高于一般人群(调整后RR=1.24,95%CI: 1.15-1.34,P < 0.001)。(3)发病时序关系的荟萃分析结果显示,在帕金森病诊断前(校正的HR=1.26,95%CI: 1.18-1.35;P < 0.001)或帕金森病诊断后(校正的RR=1.40,95%CI: 1.20-1.80,P < 0.001),患者炎症性肠病的发生率明显增高。排除1项异质性研究后发现,溃疡性结肠炎(校正的HR=1.25,95%CI: 1.13-1.38,P < 0.001)或克罗恩病(校正的HR=1.33,95%CI: 1.21-1.45,P < 0.001)患者同时发生帕金森病的合并风险显著增加。(4)亚组分析显示,在特定性别的分析中未观察到男性(校正的HR=1.23,95%CI: 1.10-1.39)和女性(校正的HR=1.26,95%CI: 1.10-1.43)之间存在显著的风险差异,但老年(> 65岁)炎症性肠病患者(校正的HR=1.32,95%CI: 1.17-1.48)可能比年轻(≤65岁)炎症性肠病患者(校正的HR=1.24,95%CI: 1.08-1.42)有更高的帕金森病发病风险。未接受抗肿瘤坏死因子α或硫唑嘌呤治疗的炎症性肠病患者发生帕金森病的风险明显增高(校正的HR=1.6,95%CI: 1.2-2.2)。(5)现有的观察性研究证据表明,炎症性肠病与帕金森病之间在发病风险和时间方面存在一定的相关性,炎症性肠病可能会适度增加帕金森病的风险,老年炎症性肠病患者(> 65岁)是帕金森病的高危人群,且与性别因素无关,炎症性肠病患者早期抗炎治疗可能会降低这一风险,文章结果高度提示了亟需对炎症性肠病患者制定帕金森病的个体化筛查策略。但由于文章中纳入的研究大多为观察性研究,因此未来还需要更多的随机对照试验来证实炎症性肠病与帕金森病的确切患病关联。

https://orcid.org/0000-0003-0313-3434 (Ren-Shi Xu); https://orcid.org/0000-0001-9003-0489 (Zheng-Bing Xiang)

关键词: 神经退行性病, 帕金森病, 炎症性肠病, 克罗恩病, 溃疡性结肠炎, 神经变性病, 中枢神经系统, 系统评价, 荟萃分析, 脑肠轴, 神经炎症

Abstract: Growing evidence suggests that there are similar pathological mechanisms and closely related pathogenic risk factors for inflammatory bowel disease (IBD) and Parkinson’s disease (PD). However, the epidemiological features of these two diseases are different. This review systematically evaluated the relationship between inflammatory bowel diseases and Parkinson’s disease risk. We searched PubMed, Embase, and Cochrane databases to retrieve observational studies of IBD and PD published from inception to October 2019. Nine observational studies, involving 12,177,520 patients, were included in the final analysis. None of the studies had Newcastle–Ottawa Scale scores that suggested a high risk of bias. After adjusting for confounders and excluding heterogeneous studies, the overall risk of PD was significantly higher in IBD patients than in the general population (adjusted risk ratio [RR] = 1.24, 95% confidence interval [CI]: 1.15–1.34, P < 0.001). A meta-analysis of the temporal relationship revealed that the incidence of IBD was significantly increased before (adjusted hazard ratio [HR] = 1.26, 95% CI: 1.18–1.35, P < 0.001) and after (adjusted RR = 1.40, 95% CI: 1.20–1.80, P < 0.001) PD diagnosis. After excluding a heterogeneous study, the pooled risk of PD development in patients with ulcerative colitis (adjusted HR = 1.25, 95% CI: 1.13–1.38, P < 0.001) or Crohn’s disease (adjusted HR = 1.33, 95% CI: 1.21–1.45, P < 0.01) was significantly increased. Subgroup analysis revealed no significant differences in risk between men (adjusted HR = 1.23, 95% CI: 1.10–1.39) and women (adjusted HR = 1.26, 95% CI: 1.10–1.43); however, older (> 65 years old) IBD patients (adjusted HR = 1.32, 95% CI: 1.17–1.48) may have a higher risk than younger (≤ 65 years old) patients (adjusted HR = 1.24, 95% CI: 1.08–1.42). Patients with IBD who were not treated with anti-tumor necrosis factor-α or azathioprine had significantly higher PD risk (adjusted HR = 1.6, 95% CI: 1.2–2.2). Thus, our meta-analysis indicates a certain correlation between IBD and PD, and suggests that IBD may moderately increase PD risk regardless of sex, especially in patients over 65 years of age. Moreover, early anti-inflammatory therapies for IBD might reduce the risk of developing PD. Our findings suggest an urgent need for an individualized screening strategy for patients with IBD. However, most studies included in this paper were observational, and more randomized controlled trials are needed to confirm the precise association between IBD and PD.

Key words: brain-gut axis, central nervous system, Crohn’s disease, inflammatory bowel diseases, meta-analysis, neurodegenerative disease, neuroinflammation, Parkinson’s disease, systematic review, ulcerative colitis 

中图分类号: